Retatrutide Weekly Update
Retatrutide Weekly Update
Maintained by the ThePeptide.ca Research Team · Updated weekly · Last updated: August 31, 2026 · Every item links to a verified primary source and is labelled by evidence type.
Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist. It is not approved by Health Canada, the FDA, or any other regulator. Eli Lilly has completed five positive Phase 3 readouts across the TRIUMPH and TRANSCEND programs and has stated it plans to file for FDA approval in 2027. One Phase 3 dataset — TRANSCEND-T2D-1 — has cleared peer review in The Lancet; the remaining figures circulating publicly come from company press releases. In August 2026, Lilly opened a narrow US expanded-access (compassionate-use) pathway allowing a limited number of patients who cannot enrol in a trial to request the drug before approval; this is not an approval and does not apply in Canada. In Canada, retatrutide has no Drug Identification Number and may not be sold or marketed for human use.
Compound reference
| Compound | Retatrutide (LY3437943) |
| Class | Triple receptor agonist — GIP / GLP-1 / glucagon |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4,731.42 g/mol |
| CAS number | 2381089-83-2 |
| PubChem CID | 171934787 (indexed as retatrutide sodium salt) |
| Regulatory status | Investigational. No Health Canada DIN. No FDA approval. Filing anticipated 2027. |
| Registrational program | TRIUMPH (obesity, knee OA, sleep apnea) and TRANSCEND (type 2 diabetes, CKD) |
How to read this page
Every item is tagged with the type of evidence behind it, because a company press release and a peer-reviewed publication are not the same thing — and most coverage of this compound does not distinguish them.
Peer-reviewed Published in a journal after review.
Company release Sponsor-reported topline data, not yet peer-reviewed.
Regulatory Action or notice from a regulator or court.
Conference Presented at a scientific meeting.
Analysis Secondary reporting or expert commentary.
Weekly log
Quiet seven days; Lilly’s August enforcement escalation logged for the record
Week of Aug 31 – Sep 6, 2026No new retatrutide clinical readouts, peer-reviewed publications, or regulatory actions were identified in the past seven days; retatrutide remains investigational and unapproved by Health Canada, the FDA, and every other regulator, and Lilly’s stated plan to file for FDA approval in 2027 is unchanged. This entry also records one verified primary-source development from August 12, 2026 — Eli Lilly’s escalation against the illegal retatrutide market — that had not previously been logged on this page.
Company releaseLilly escalates enforcement against the illegal retatrutide market
In an investor release dated August 12, 2026, Eli Lilly called on drug regulators, customs and law-enforcement agencies, online platforms, payment processors, shipping companies and healthcare providers to help shut down the illegal sale of unapproved retatrutide. Lilly said it had referred more than 200 individuals and entities to law enforcement and regulators, identified more than 14,000 websites, advertisements, social-media posts and product listings unlawfully marketing retatrutide across more than 100 countries, and filed six new lawsuits against US sellers including compounding pharmacies and medical spas. Lilly’s chief medical officer stated that “what is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk.” This is a company enforcement statement, not new clinical evidence; retatrutide remains investigational and is not approved by Health Canada, the FDA, or any other regulator.
Source: Eli Lilly investor release, August 12, 2026 · STAT News
AnalysisNo new trial, publication, or regulatory developments in the past seven days
A review of clinical-trial readouts, peer-reviewed journals (via PubMed), regulator notices (FDA, Health Canada, EMA) and Eli Lilly’s investor releases identified no new retatrutide developments in the seven days to August 31, 2026. The most recent citable dataset remains the peer-reviewed TRANSCEND-T2D-1 publication in The Lancet (June 2026; indexed at PubMed as PMID 42250575); the remaining Phase 3 figures across the TRIUMPH and TRANSCEND programs remain company-reported and not yet peer-reviewed, and the cardiovascular-outcomes trial TRIUMPH-Outcomes has not reported. The next major scientific meeting likely to feature retatrutide data, the EASD Annual Meeting, is scheduled for September 28 – October 2, 2026, in Milan.
Source: PubMed (retatrutide, by date) · EASD 2026
Quiet week: no new primary-source developments
Week of Aug 10 – 16, 2026No new clinical readouts, peer-reviewed publications, or regulatory actions on retatrutide were identified this week. Retatrutide remains investigational and unapproved by Health Canada, the FDA, and every other regulator, and Lilly’s stated plan to file for FDA approval in 2027 is unchanged.
AnalysisNo new data, publications, or regulatory actions this week
A review of clinical-trial readouts, peer-reviewed journals (via PubMed), regulator notices (FDA, Health Canada, EMA), scientific conferences, and Eli Lilly’s investor releases identified no substantive new retatrutide development for the week of August 10, 2026. The most recent citable dataset remains the peer-reviewed TRANSCEND-T2D-1 publication in The Lancet (June 2026); the remaining Phase 3 figures across the TRIUMPH and TRANSCEND programs remain company-reported and not yet peer-reviewed. Ongoing trade and clinical commentary continued to discuss Lilly’s August 3 expanded-access (compassionate-use) announcement, but reported no new efficacy or safety data; that development is logged in the week of August 3 entry below.
Source: Eli Lilly investor news (no new retatrutide release this week) · PubMed (retatrutide, by date)
Lilly opens narrow pre-approval access to retatrutide amid physician pushback
Week of Aug 3 – 9, 2026Eli Lilly confirmed on August 3, 2026 that it will let a limited number of patients apply for retatrutide before FDA approval through an expanded-access (compassionate-use) pathway, subject to narrow eligibility criteria. No new efficacy or safety data were released; retatrutide remains investigational and unapproved everywhere, and the pathway is a US mechanism that does not apply in Canada.
Company statementLilly formalises a limited expanded-access program
In statements to reporters on August 3, 2026, Lilly said it would allow patients who cannot enrol in a clinical trial to request retatrutide ahead of FDA approval. A company spokesperson said: “For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance.” Reported eligibility criteria are: age 18 or older; severe obesity unresponsive to existing approved obesity medication; at least two serious or life-threatening obesity-related complications requiring medical care; and inability to participate in ongoing retatrutide or comparable investigational trials. This was a statement confirmed to the press rather than a formal press release or peer-reviewed report, and Lilly still plans to file for FDA approval in 2027.
Source: STAT News · Reuters (syndicated)
AnalysisClinician reaction is mixed; criteria are narrow
The move follows June 2026 STAT reporting that Lilly had granted a single 79-year-old patient compassionate-use access in April 2026, which prompted other physicians — including Spencer Nadolsky and Mike Albert — to say their own access requests had gone weeks without a substantive response. Coverage this week noted the published criteria are strict enough that most patients seeking the drug would not qualify. No clinical outcome from any expanded-access use has been reported, and none should be inferred; this is an access-policy development, not new trial evidence.
Source: AJMC
Canadian enforcement lands; filing timeline digested
Week of Jul 27 – Aug 2, 2026Health Canada publicly announced a permanent court injunction against a Canadian online peptide retailer — the first Canadian enforcement development of this scale to touch the compounds named in its April advisory, retatrutide among them. No new retatrutide trial data this week; coverage focused on digesting Lilly’s 2027 filing timeline.
RegulatoryHealth Canada announces permanent injunction against Canlab Research
The Superior Court of Québec granted the injunction on June 11, 2026; Health Canada announced it publicly in late July. It permanently bars the company from selling unauthorized injectable peptides and from advertising them “including through any website or social media platform accessible with a Canadian Internet Protocol (IP) address.” Retatrutide was among the compounds named in Health Canada’s April 9, 2026 advisory.
Source: Health Canada news release · Our full analysis: FDA & Peptides in 2026
AnalysisCoverage frames the 2027 FDA filing as a delay
Following Lilly’s July 23 confirmation that it will file for FDA approval in 2027, several outlets characterised the timeline as a delay against earlier expectations. No change to the underlying data was reported; the compound remains investigational everywhere.
Source: CNBC · BioPharma Dive
TRIUMPH-2 and TRIUMPH-3 read out; Lilly commits to a 2027 filing
Week of Jul 20 – 26, 2026Lilly reported topline results from two more Phase 3 obesity trials, completing the core Phase 3 dataset, and said it will seek FDA approval in 2027. The cardiovascular readout in TRIUMPH-3 was neutral, not protective — a limitation worth stating plainly.
Company releaseTRIUMPH-2 and TRIUMPH-3 topline results
TRIUMPH-2 (type 2 diabetes with obesity, n≈1,152) and TRIUMPH-3 (severe obesity with established cardiovascular disease, n≈1,949) reported topline results over 80 weeks, with both trials meeting their primary endpoints. See the linked source for the reported figures.
Company releaseCardiovascular outcome was neutral, not protective
TRIUMPH-3 recorded 44 major adverse cardiovascular events in the retatrutide arms versus 52 on placebo — a five-point MACE hazard ratio of 0.82 (95% CI 0.55–1.22). The confidence interval crosses 1.0, so the result is not statistically significant; Lilly noted events occurred less frequently than anticipated in both arms. Cardiovascular risk factors also moved in a favourable direction in the treatment arm (see source). The larger TRIUMPH-Outcomes study is designed to answer the events question.
Source: Fierce Biotech
First peer-reviewed Phase 3 dataset published in The Lancet
Week of Jun 1 – 7, 2026TRANSCEND-T2D-1 became the first retatrutide Phase 3 dataset to clear peer review, published in The Lancet and presented at the ADA Scientific Sessions. This is the single most citable retatrutide result to date.
Peer-reviewedTRANSCEND-T2D-1 published in The Lancet
TRANSCEND-T2D-1 studied 537 adults with type 2 diabetes across 48 sites over 40 weeks. As the first peer-reviewed Phase 3 retatrutide dataset, it is the single most citable reference on the compound to date; see the publication for its full glycaemic, weight and safety results. Gastrointestinal adverse events were reported as mild to moderate, with no severe hypoglycaemia.
Source: The Lancet, doi:10.1016/S0140-6736(26)00967-0 (online June 6, 2026)
ConferenceTRIUMPH-1 and TRANSCEND-T2D-1 presented at ADA 2026
Both datasets were presented at the American Diabetes Association 86th Scientific Sessions on June 6, 2026, in New Orleans; see the linked coverage for the reported secondary outcomes.
Source: Cleveland Clinic Journal of Medicine, ADA 2026 coverage
TRIUMPH-1 pivotal obesity results reported
Week of May 18 – 24, 2026The pivotal obesity trial (TRIUMPH-1) reported topline results at 80 weeks. A methodological point worth flagging: Lilly reported both a treatment-regimen and an efficacy estimand, while most coverage quotes only the larger one.
Company releaseTRIUMPH-1 topline: both estimands reported
In 2,339 randomised participants over 80 weeks, Lilly reported outcomes under both estimands; see the linked source for the full figures.
A recurring reporting error is worth noting: the widely circulated 30.3% figure comes from a pre-specified extension at 104 weeks in the 532 participants with BMI ≥35 who continued — not the whole trial population at 80 weeks.
Source: Eli Lilly release, May 21, 2026
Company releaseTolerability: discontinuation rose in the higher-strength arms
Discontinuation due to adverse events rose across the trial arms, reaching 11.3% in the highest-strength arm versus 4.9% on placebo. Nausea was the most common adverse event, alongside diarrhoea, constipation and vomiting. See the linked source for the full arm-by-arm figures.
Source: The Pharmaceutical Journal
First Phase 3 readout — and a new safety signal
Week of Dec 8 – 14, 2025TRIUMPH-4 was the first Phase 3 trial to report, covering obesity and knee osteoarthritis. It also surfaced dysesthesia — a safety signal that had not appeared in Phase 2 and remains under-reported in most coverage.
Company releaseTRIUMPH-4: obesity and knee-osteoarthritis topline
In 445 adults with obesity or overweight plus knee osteoarthritis and without diabetes (BMI ≥27; baseline mean 112.7 kg), 68 weeks of retatrutide reported topline results across the active arms. See the linked source for the reported figures.
Source: Eli Lilly release, December 2025
Company releaseKnee pain outcomes
The trial also reported knee-pain and function (WOMAC) outcomes; see the linked source for the reported figures.
Source: Patient Care Online
AnalysisNew dysesthesia signal not seen in Phase 2
Dysesthesia — an abnormal sense of touch in which normal sensations feel unusual or painful — occurred in up to 20.9% of participants on retatrutide, versus 0.7% on placebo. Lilly reported that these events did not appear to lead to discontinuation. The signal had not emerged in Phase 2 testing. Overall discontinuation in TRIUMPH-4 reached 18.2% versus 4.0% on placebo.
Source: BioSpace
The trial programs, in brief
Retatrutide is being studied across two registrational programs. Keeping them straight matters, because coverage frequently conflates them.
| Program | Focus | Trials referenced to date |
|---|---|---|
| TRIUMPH | Obesity, knee osteoarthritis, obstructive sleep apnea | TRIUMPH-1 (obesity), TRIUMPH-2 (T2D with obesity), TRIUMPH-3 (severe obesity with CVD), TRIUMPH-4 (knee OA), TRIUMPH-Outcomes (cardiovascular events) |
| TRANSCEND | Type 2 diabetes and chronic kidney disease | TRANSCEND-T2D-1 (published), TRANSCEND-CKD (design published) |
Program design details are published in the peer-reviewed literature: PMID 41090431 (TRIUMPH rationale and design) and PMID 41160422 (TRANSCEND-CKD).
Retatrutide and Canadian law
Retatrutide is not authorized for sale in Canada. It has no Drug Identification Number, and Health Canada regulates injectable peptides of this kind as prescription drugs under the Food and Drugs Act. Health Canada has stated explicitly that “research use only” labelling does not make such products legal or exempt them from regulatory requirements. Materials supplied for laboratory research are a separate category and are not for human use.
Full context: FDA & Peptides in 2026: the PCAC vote, retatrutide’s Phase 3 data and what’s legal in Canada.
Related research resources
- Retatrutide research guide — mechanism, pharmacology, purity and sourcing
- Semaglutide vs tirzepatide vs retatrutide — single, dual and triple agonism compared
- How to read a peptide Certificate of Analysis
- Published lot COAs — third-party HPLC-UV results, linked to the testing lab’s own portal
Update log. July 31, 2026 — Page created. Launch archive covers the week of Jul 27 2026 back to the first Phase 3 readout in Dec 2025, with all figures verified against primary sources and both TRIUMPH-1 estimands reported. August 6, 2026 — Added the week of Aug 3, 2026: Lilly opened a limited pre-approval expanded-access pathway for retatrutide; no new trial data this week. Current-status block updated to note the expanded-access pathway. August 11, 2026 — Added the week of Aug 10, 2026: a quiet week with no new primary-source developments. Status re-verified against Eli Lilly investor releases, PubMed, and FDA/Health Canada/EMA notices and left unchanged. August 31, 2026 — Added the week of Aug 31, 2026: no new primary-source developments in the past seven days. Also logged, for the record, Eli Lilly’s August 12 investor release escalating enforcement against the illegal retatrutide market (more than 200 referrals to authorities, more than 14,000 listings across over 100 countries, six new US lawsuits), which had not previously appeared on this page. Status re-verified against Lilly investor releases, PubMed, and FDA/Health Canada/EMA notices and left unchanged.